₹150 Cr, a rare plasma plant, and global ambitions: PlasmaGen’s big leap

Bengaluru-based PlasmaGen Biosciences has raised ₹150 crore in a minority equity round led by ViNS Bioproducts, valuing the company at ₹1,500+ crore.

First, the backstory

PlasmaGen Biosciences, founded in 2010, operates in a niche but critical segment—blood plasma–derived therapeutics. These are life-saving products used to treat immune deficiencies, bleeding disorders, and other serious conditions. India has very limited plasma fractionation capacity, making this space both capital-intensive and strategically important.

Why this funding is significant

• PlasmaGen has now raised ₹600+ crore in total funding

• The round reflects strong investor confidence in its manufacturing-led business model

• Valuation crossing ₹1,500 crore signals PlasmaGen’s transition from a domestic player to a global biopharma platform

In simple terms: investors are backing scale, not just promise.

The real growth driver: Manufacturing

In 2024, PlasmaGen commenced commercial operations at its high-tech plasma fractionation facility—

• One of only five such facilities in India

• Built to global quality and compliance standards

• Already driving rapid revenue growth within a year of operations

This facility is the backbone enabling international expansion.

Where the money will go

The fresh ₹150 crore will be used to:

1. Scale international operations

2. Expand the plasma-derived product portfolio

3. Strengthen leadership and organisational depth

This isn’t survival capital—it’s growth capital.

Global ambitions, finally taking shape

PlasmaGen has:

• Identified distribution partners in key export markets

• Started advancing regulatory approvals for international sales

• Continued expanding its domestic footprint in high unmet-need therapies

The strategy is clear: India-first manufacturing, global-first markets.

Leadership upgrade to match scale

To support its next phase, PlasmaGen has strengthened its top team:

• Vivek V Kamath — CEO

• Sethu Madhavan — COO (Manufacturing & Technical Operations)

• Arnav Jain — CFO

This signals a shift from founder-led execution to institution-ready governance.

The long-term vision

Founder & Executive Chairman Vinod Nahar sums it up best:

Build a world-class, India-based plasma biopharmaceutical platform with global quality and real patient impact.

If executed well, PlasmaGen could become a strategic healthcare partner for both Indian and global health systems.

The UnlistedZone takeaway

PlasmaGen’s ₹150 crore raise isn’t just about funding—it’s about proof of scale. With manufacturing live, revenues accelerating, and global markets in sight, the company is moving from "potential" to platform. And in biopharma, that’s where real value gets created.